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Extracellular matrixIdiopathic pulmonary ﬁbrosis (IPF) is characterized by the progressive and ultimately fatal accumulation of
ﬁbroblasts and extracellular matrix in the lung that distorts its architecture and compromises its function.
IPF is now thought to result from wound-healing processes that, although initiated to protect the host
from injurious environmental stimuli, lead to pathological ﬁbrosis due to these processes becoming aberrant
or over-exuberant. Although the environmental stimuli that trigger IPF remain to be identiﬁed, recent evi-
dence suggests that they initially injure the alveolar epithelium. Repetitive cycles of epithelial injury and re-
sultant alveolar epithelial cell death provoke the migration, proliferation, activation and myoﬁbroblast
differentiation of ﬁbroblasts, causing the accumulation of these cells and the extracellular matrix that they
synthesize. In turn, these activated ﬁbroblasts induce further alveolar epithelial cell injury and death, thereby
creating a vicious cycle of pro-ﬁbrotic epithelial cell-ﬁbroblast interactions. Though other cell types certainly
make important contributions, we focus here on the “pas de deux” (steps of two), or perhaps more appropri-
ate to IPF pathogenesis, the “folie à deux” (madness of two) of epithelial cells and ﬁbroblasts that drives the
progression of pulmonary ﬁbrosis. We describe the signaling molecules that mediate the interactions of these
cell types in their “ﬁbrosis of two”, including transforming growth factor-β, connective tissue growth factor,
sonic hedgehog, prostaglandin E2, angiotensin II and reactive oxygen species. This article is part of a Special
Issue entitled: Fibrosis: Translation of basic research to human disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Fibrosis characterizes many chronic diseases that result in end-
stage organ failure, and consequently is a major cause of morbidity
and mortality. The pathogenesis of ﬁbrosis in many of these diseases
is thought to involve aberrant or over-exuberant wound-healing pro-
cesses initiated to protect the host from injurious stimuli [1]. In re-
sponse to noxious stimuli of many different types, aberrant repair
processes can produce the common result of excessive deposition of ex-
tracellular matrix that disrupts normal tissue homeostasis. Repair pro-
cesses involve multiple cell types, including epithelial cells, ﬁbroblasts,AEC, alveolar epithelial cell;
ssue growth factor; Shh, sonic
gen species; H2O2, hydrogen
s: Translation of basic research
and Inﬂammatory Diseases,
8301, Charlestown, MA 02129,
rights reserved.endothelial cells, pericytes and leukocytes, all of which potentially in-
teract with each other. Interactions between two cell types in particular,
alveolar epithelial cells and ﬁbroblasts, appear to be central to the path-
ogenesis of idiopathic pulmonary ﬁbrosis (IPF) [2].
IPF is characterized by progressive ﬁbrosis, with excessive matrix
deposition leading to destruction of lung architecture and ultimately
fatal impairment of lung function. IPF has a heterogenous clinical
course, but the median survival after diagnosis is only 2.5–3.5 years
[2]. Althoughmuch of the pathogenesis of IPF remains to be elucidated,
ﬁbroblasts and epithelial cells have emerged as principal players in this
disease, in particular myoﬁbroblasts and type II alveolar epithelial cells.
Fibroblasts and myoﬁbroblasts accumulate in IPF lungs in “ﬁbroblastic
foci” that, as the predominant sites of excess matrix production, can
be thought of as the leading edge of active ﬁbrosis [3]. Fibroblast activa-
tion and accumulation in IPF, however, appears to be fundamentally
driven by recurrent and/or non-resolving injury to the alveolar epithe-
lium, and therefore in another sense, the injured alveolar epithelium
can be thought of as the leading edge of active ﬁbrosis. With ﬁbroblasts
and alveolar epithelial cells being in close apposition in the lung, it is not
surprising that the interactions between these two key cellular players
contribute to the development of pulmonary ﬁbrosis. Though other
cell types certainly make important contributions, we will focus on
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pathogenesis, the “folie à deux” (madness of two) of epithelial cell-
ﬁbroblast interactions as critical drivers of pulmonary ﬁbrosis.Whereas
the source of the ﬁbroblasts and myoﬁbroblasts that accumulate in the
lung asﬁbrosis develops –whether these cells arise from resident ﬁbro-
blasts, resident epithelial cells or circulating precursors – has been an
area of controversy, the pro-ﬁbrotic effects of the interactions of ﬁbro-
blasts andmyoﬁbroblastswith resident lung epithelial cells has become
increasingly clear. We describe the role of several important mediators
in orchestrating the pro-ﬁbrotic interactions of epithelial cells andﬁbro-
blasts in their “ﬁbrosis of two”, including transforming growth factor-β,
connective tissue growth factor, sonic hedgehog, prostaglandin E2,
angiotensin II and reactive oxygen species (Fig. 1).
2. Epithelial cells: targeted cells in IPF
Accumulating evidence points toward recurrent and/or non-
resolving injury to the lung epithelium as the “prime mover” of pul-
monary ﬁbrosis. Although the cause of this injury in IPF remains enig-
matic, the footprints of lung epithelial injury are manifest, both in the
form of (1) increased epithelial cell death, and (2) phenotypic alter-
ations of the surviving epithelial cells. Increased numbers of apoptotic
and necrotic cells have been observed in both the alveolar and bron-
chial epithelia of IPF patients [4–6]. Surviving epithelial cells in IPF
lungs demonstrate several altered phenotypes [7]. Cuboidal epithelial
cells representing type II alveolar epithelial cell (AEC) hyperplasia
and/or bronchiolar basal cell proliferation line thickened ﬁbrotic
alveolar septa; single layers of ﬂattened epithelial cells suggestive
of squamous metaplasia frequently are present overlying ﬁbroblastic
foci; and single-layered columnar or pseudostratiﬁed columnar epithe-
lial cells often line the abnormally enlarged, restructured air spaces
of honeycomb lung. These morphological changes are associated
with modiﬁcations of epithelial cell expression of speciﬁc cytokeratins,
suggesting that in addition to their morphology, the differentiation
states and functions of epithelial cells are likely profoundly altered in
IPF. Of note, although IPF has been traditionally viewed as affecting
the parenchymal lung rather than the airways, a potentially central
role for the bronchial epithelium in addition to the alveolar epithelium
in IPF pathogenesis has been suggested by the recent association of aCTGF
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αvβ6
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ANG II
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Fig. 1. Epithelial-ﬁbroblast interactions drive the progression of idiopathic pulmonary ﬁbro
apoptosis and their production and/or activation of pro-ﬁbrotic mediators, including TGF-β
activation andmyoﬁbroblast differentiation, resulting in the accumulationmyoﬁbroblasts an
AEC injury and apoptosis, including ANGII and reactive oxygen species such as H2O2, creatin
gression of IPF. PGE2 normally mediates anti-ﬁbrotic interactions between epithelial cells
responsiveness. Green arrows indicate pro-ﬁbrotic epithelial cell-ﬁbroblast interactions;
CTGF, connective tissue growth factor; Shh, sonic hedgehog; ANG II, angiotensin II; H2O2, hgenetic variant in mucin 5B (MUC5B) with both familial and sporadic
IPF [8].
The potential of epithelial injury in general to cause pulmonary
ﬁbrosis has been demonstrated in several mouse models. Induction of
pulmonary epithelial cell death in mice, either by pulmonary delivery
of anti-Fas antibody [9,10] or transgenic overexpression of transforming
growth factor-β (TGF-β) [11], results in the development of ﬁbrosis, as
does genetically targeting diptheria toxin-induced injury to alveolar
epithelial cells [12]. Additionally, inhibition of apoptosis attenuates
the ﬁbrosis induced by bleomycin challenge, the most commonly used
mouse model of pulmonary ﬁbrosis [13].
Finally, in addition to noxious stimuli in the external environment,
alterations in the internal environment of epithelial cells can also lead
to their death and promote pulmonary ﬁbrosis. For example, the mu-
tations in the gene encoding surfactant protein C (SFTPC) that have
been associated with familial pulmonary ﬁbrosis (familial interstitial
pneumonia) cause SFTPC misfolding, leading to protein accumula-
tion and endoplasmic reticulum (ER) stress [14–17]. Unresolved or
prolonged ER stress activates cellular apoptotic pathways, and the
resulting epithelial cell death may cause the pulmonary ﬁbrosis
that affects these SFTPC mutation kindreds [18]. Thus epithelial cell
injury and death, albeit due to a variety of causes and through a va-
riety of mechanisms, appears to be a common initiating pathway to
ﬁbrosis in the lung.
3. Epithelial cell-to-ﬁbroblast interactions: how injured epithelial
cells activate ﬁbroblasts
Areas of AEC apoptosis and foci of α-smooth muscle actin
(αSMA)-positive myoﬁbroblasts co-localize in the lungs of IPF pa-
tients [6], making it plausible for these two cell types to directly inﬂu-
ence each other as ﬁbrosis develops. The ability of injured epithelial
cells to affect local ﬁbroblast behavior in a paracrine fashion has
been demonstrated by in vitro co-culture experiments. In these ex-
periments, mechanical injury to epithelial cells induced the expres-
sion of α-SMA and type I and III collagen in co-cultured ﬁbroblasts
by stimulating the activation of TGF-β in the extracellular matrix
[19]. In addition to TGF-β, a growing list of mediators has been
found to contribute to the ability of injured epithelial cells activateInjured AEC
PGE2
Apoptotic AEC
Myofibroblast
Fibroblast
Collagen
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sis. Environmental stimuli initially injure alveolar epithelial cells (AECs), inducing their
, CTGF and Shh. These AEC-derived mediators direct ﬁbroblast migration, proliferation,
d extracellular matrix in the lung. Myoﬁbroblasts in turn secrete mediators that amplify
g a vicious cycle of pro-ﬁbrotic epithelial cell-ﬁbroblast interactions that drives the pro-
and ﬁbroblasts, but its production by AECs is reduced in IPF, as is ﬁbroblast PGE2--
red arrows indicate anti-ﬁbrotic interactions. TGF-β, transforming growth factor-β;
ydrogen peroxide; PGE2, prostaglandin E2.
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tive tissue growth factor (CTGF);morphogens, such as sonic hedgehog
(Shh), and lipid mediators, such as prostaglandin E2 (PGE2) [20–24].
Many of these mediators, such as TGF-β, CTGF and Shh promote ﬁbro-
blast activation, whereas others such as PGE2 are suppressive (Fig. 1).
In the sections that follow, TGF-β, CTGF, Shh and PGE2 are discussed as
important examples of mediators through which injured epithelial
cells regulate ﬁbroblast activation, but are certainly not a complete
list of the molecules involved in epithelial cell-to-ﬁbroblast interac-
tions in ﬁbrosis.
3.1. Transforming growth factor-beta (TGF-β)
TGF-β is a member of the TGF-β super-family, which in addition to
TGF-β includes related cytokines such as bone morphogenic proteins,
activins and inhibins [25]. Mammals have three different forms of
TGF-β (TGF-β1, -β2, and -β3), each of which are widely expressed
throughout the body [26]. All three isoforms initiate their cellular ef-
fects using the same high-afﬁnity cell surface receptors (TGF-β type I
and type II receptors) [27,28]. But despite their common receptor
usage, the isoforms have differing biological functions, as indicated
by the differing phenotypes of mice deﬁcient for each. TGF-β1
null mice develop severe multi-focal inﬂammation and die within
3 weeks of birth [29,30], whereas TGF-β2 nullmice die in the perinatal
period due to cyanotic heart disease and pulmonary insufﬁciency [31],
and TGF-β3 null mice die of craniofacial defects, most notably cleft
palate [32]. Taken together, these phenotypes indicate that TGF-β sig-
naling is important for tissue growth and morphogenesis during em-
bryonic development, and for tissue homeostasis thereafter. When
tissue homeostasis is perturbed by injury, however, TGF-β acts as a
major pro-ﬁbrotic cytokine, potently increasing ﬁbroblast recruit-
ment, proliferation, differentiation into myoﬁbroblasts and produc-
tion of extracellular matrix [33]. Delivery of this cytokine by itself
to the rodent lung through intratracheal transfer of active TGF-β1 in
an adenoviral vector is sufﬁcient to induce pulmonary myoﬁbroblast
accumulation and ﬁbrosis [34,35]. Conversely, inhibiting TGF-β
with neutralizing antibodies or a type I receptor inhibitor suppresses
experimental pulmonary ﬁbrosis [36,37]. Importantly, increased
endogenous expression of TGF-β is not by itself sufﬁcient to increase
TGF-β function, because all three TGF-β isoforms are generated and
are present in tissues as inactive latent precursors. As discussed
below, epithelial cells have been shown to mediate the activation of
latent TGF-β in the lung, and consequently to play a critical role in
the presentation of active TGF-β to ﬁbroblasts in the pathogenesis of
pulmonary ﬁbrosis.
3.1.1. Activation of TGF-β by epithelial cell integrins
The three TGF-β isoforms are produced in the form of small latent
complexes (SLCs), in which the bioactive TGF-β peptides form non-
covalent associations with a latency-associated peptide (LAP) [26].
Further, SLCs are usually secreted in association with latent TGF-β
binding proteins (LTBPs) as large latent complexes (LLCs). LLCs are
sequestered in the extracellular matrix through the covalent binding
of LTBPs to extracellular matrix proteins, such as ﬁbrillin and ﬁbro-
nectin [26]. For TGF-β to exert biological effects, it must be activated
from these latent complexes. The changes in TGF-β's interactions
with its LAP required for TGF-β activity can be accomplished by either
non-proteolytic or proteolytic mechanisms that result in conforma-
tional changes or cleavage of the LAP respectively [26,38,39]. The
non-proteolytic activation of TGF-β by epithelial cells, and the presen-
tation of the active TGF-β produced to ﬁbroblasts, appears to be an
epithelial cell-to-ﬁbroblast interaction that is central to the develop-
ment of pulmonary ﬁbrosis.
Epithelial cells induce activating conformational changes in latent
TGF-β complexes through their integrins. Integrins are cell adhesion
molecules and transmembrane receptors that link the cytoskeletonto the extracellular matrix, and in addition to adhesion, regulate multi-
ple fundamental cell processes including cell migration, proliferation
and differentiation [40,41]. Integrins are composed of α and β subunits
(18 α and 8 β subunits) that heterodimerize to form 24 αβ combina-
tions [42]. Eight of these, including all ﬁve αν-containing integrins
(ανβ1, ανβ3, ανβ5, ανβ6 and ανβ8), are capable of binding ligands
with an arginine-glycine-aspartate (RGD) motif. The LAPs of both
TGF-β1 and TGF-β3 have RGD sequences, and these two TGF-β
isoforms can be activated in vitro by at least four of the αν-containing
integrins (ανβ3, ανβ5, ανβ6, ανβ8) [42].
Activation of latent TGF-β speciﬁcally by the ανβ6 integrin ap-
pears to centrally important in the development of pulmonary ﬁbro-
sis. Genetic deletion of the β6 subunit, or antibody blockade of
ανβ6, suppress TGF-β signaling in the lung after injury, and protect
mice from the development of pulmonary ﬁbrosis induced by
bleomycin or radiation [43–45]. Lung expression of ανβ6 appears to
be restricted to epithelial cells, underscoring the fundamental involve-
ment of epithelial cell-to-ﬁbroblast interactions in the pro-ﬁbrotic
behaviors induced in ﬁbroblasts by TGF-β during the development
of pulmonary ﬁbrosis. The ability of epithelial cell ανβ6 to mediate
latent TGF-β activation is dependent on epithelial cell cytoskeletal
function. The cytoplasmic tail of the β6 subunit binds to the actin
cytoskeleton, and disruption of this binding by mutation of the β6
cytoplasmic domain, or inhibition of actin polymerization with cyto-
chalasin D, abolish epithelial cell activation of latent TGF-β [43].
Consistent with the activation of this pathway in pulmonary ﬁbro-
sis, markedly increased lung epithelial ανβ6 expression is present in
mouse lungs post-bleomycin challenge, and in human lungs with
usual interstitial pneumonia (UIP) pattern pulmonary ﬁbrosis [45,46].
This increased ανβ6 expression may itself be driven by active TGF-β.
TGF-β induces the expression of the β6 subunit gene (itgb6) through
the transcription factor Ets1 [47,48], and this process is inhibited by
neutralizing β6 antibody [49]. ανβ6 integrin-mediated activation of
latent TGF-β may therefore be ampliﬁed in pulmonary ﬁbrosis by a
feed-forward loop of increased TGF-β activation and increased ανβ6
expression.
3.1.2. Pro-ﬁbrotic effects of TGF-β on ﬁbroblasts
Once freed from its latent complexes by epithelial cell integrins,
active TGF-β interacts with its receptors expressed by ﬁbroblasts to in-
duce multiple pro-ﬁbrotic behaviors. Active TGF-β ﬁrst binds to TGF-β
receptor type II (TBRII), which phosphorylates and heterodimerizes
with TGF-β receptor type I (TBRI) to form an active ligand–receptor
complex. This TGF-β–TBRII/I complex initiates pro-ﬁbrotic responses
in ﬁbroblasts through both canonical and non-canonical signaling
pathways. In the canonical TGF-β signaling pathway, activated TBRI
phosphorylates effector Smad proteins (Smad2 and Smad3), which
heterodimerize with Smad4 to form Smad2/4 or Smad3/4 complexes
[50]. These complexes translocate to the nucleus, where they bind
to Smad response elements located in the promoter regions of
pro-ﬁbrotic genes such as type I collagen, ﬁbronectin and αSMA [51].
Consistent with canonical TGF-β signaling having pro-ﬁbrotic effects,
Smad3-deﬁcient mice are protected from bleomycin-induced lung
ﬁbrosis [52].
Both the c-Abelson tyrosine kinase (c-Abl) and mitogen-activated
protein kinases (MAPKs) have been implicated in non-canonical
TGF-β signaling. c-Abl is directly activated by TGF-β in ﬁbroblasts,
and signals through Egr-1 [53]. The small molecule imatinib mesylate
potently inhibits c-Abl, as well as the platelet-derived growth factor
receptor tyrosine kinase. Imatinib was demonstrated to prevent the
development of bleomycin-induced lung ﬁbrosis in mice [54], but a
recently completed randomized placebo-controlled clinical trial of
imatinib in IPF patients showed no beneﬁt [55].
Mitogen-activated protein kinases (MAPKs) have also been shown
to be involved in non-canonical TGF-β signaling. The MAPK family of
serine-threonine protein kinases include extracellular signal–regulated
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a wide variety of cellular responses, including proliferation, differentia-
tion, and apoptosis [56,57]. In lung ﬁbroblasts, TGF-β induction of
αSMA and collagen expression has been shown to be dependent on
ERK and p38 MAPK [56,57], and p38 MAPK activation by TGF-β has
been shown to contribute to ﬁbroblast resistance to apoptosis through
the pro-survival phosphatidyl inositol 3-kinase (PI3K)/AKT pathway
[58].
3.2. Connective tissue growth factor (CTGF/CCN2)
CTGF is as amember of the CCN protein family, containing Cysteine
rich protein 61 (cyr61/CCN1), CTGF/CCN2, and Nephroblastoma
overexpressed gene (NOV/CCN3), as well as three WNT-1-inducible
signaling proteins (WISPs), WISP-1/CCN4, WISP-2/CCN5 and
WISP-3/CCN6. These proteins are characterized by an extraordinarily
high content of cysteine residues, with the position of 38 of these cys-
teines being conserved almost entirely across the six family members
[59,60]. CCN family proteins including CTGF contain four structural
modules: an insulin-like growth factor binding protein module (mod-
ule I), a von Willebrand factor type C module (module II), a
thrombospondin type I homology module (module III) and a
carboxy-terminal cysteine knot motif, heparin-bindingmodule (mod-
ule IV). These modules each have speciﬁc binding partners, including
insulin-like growth factor for module I, TGF-β for module II, speciﬁc
integrins (α4β1,α5β1,α6β1 andανβ3) and sulfated glycoconjugates
for module III, and heparin sulfate-containing proteoglycans (HSPGs)
such as syndecan 4 and perlecan for module IV [59–61].
3.2.1. Synthesis of CTGF by epithelial cells
CTGF is principally regulated at the level of transcription [62].
Its promoter region contains binding sites for multiple transcription
factors, including Smads, AP-1, Sp1, Ets-1, hypoxia-inducible factor
and serum response factor [62–66]. Stimuli able induce CTGF tran-
scription, dependent on the cell type, include TGF-β, thrombin,
lysophosphatidic acid, and mechanical stress [60,61]. Signaling path-
ways involved in the regulation of CTGF expression by these stimuli
include MAPK, protein kinase C, the small GTPase RhoA, and PI3K
[61,66–68]. Interestingly, most of the stimuli able to induce CTGF in-
duction have also been implicated in the pathogenesis of pulmonary
ﬁbrosis [36,69–72]. CTGF was originally discovered as a ‘PDGF-related
mitogen’ in the medium of cultured human umbilical vein endothelial
cells [73], but has subsequently been shown to be expressed by other
cell types, including alveolar epithelial cells [21,73]. In lung tissues
obtained from IPF patients, CTGF mRNA and protein are both in-
creased, localizing predominantly to AECs and activated ﬁbroblasts.
In contrast, CTGF-expressing AECs are sparse in the normal lung [21].
3.2.2. Pro-ﬁbrotic effects of CTGF on ﬁbroblasts
CTGF regulates multiple ﬁbroblast behaviors that contribute to ﬁ-
brosis, including ﬁbroblast adhesion, migration, proliferation, differen-
tiation, matrix production and apoptosis [74]. CTGF can induce these
behaviors either by binding to ﬁbroblast cell surface molecules directly,
or by acting as an “adapter” molecule that brings other mediators into
contact with their receptors on ﬁbroblasts [74]. CTGF can directly affect
ﬁbroblast behaviors by binding to integrins, HSPGs and the low density
lipoprotein receptor-related protein/β2-macroglobulin receptor (LRP)
[60,75–77]. For example, CTGF binding to ﬁbroblast HSPGs induces
ﬁbroblast adhesion and proliferation [77,78]. Speciﬁc CTGF binding to
the insulin-like growth factor-II (IGF-II)/mannose 6-phosphate (M6P)
receptor expressed on lung ﬁbroblasts has also recently been shown
to induce ﬁbroblast proliferation [79]. CTGF has also been shown to di-
rectly stimulate lung ﬁbroblast expression of multiple proteins known
to be elevated in IPF, including type I collagen, the cytoskeletal proteins
vinculin, moesin and ezrin, and IQ motif containing GTPase activating
protein 1 (IQGAP1), a scaffold protein that regulates cell migrationand is elevated in lung ﬁbroblasts isolated from scleroderma patients
with pulmonary ﬁbrosis [80].
In its role as an adapter molecule [74], the cytokines and growth
factors that CTGF can “present” to their speciﬁc receptors on ﬁbro-
blasts include TGF-β [81], epidermal growth factor, and insulin-like
growth factor-II [82]. This adapter function appears to be required
for at least some of the pro-ﬁbrotic effects of TGF-β on ﬁbroblasts.
Although CTGF-deﬁcient ﬁbroblasts show intact TGF-β-induced Smad
signaling, the ability of TGF-β to induce the expression of multiple
pro-ﬁbrotic mRNAs and proteins, including αSMA and type I collagen,
is impaired in these cells [83].
Pro-ﬁbrotic effects of CTGF have also been demonstrated in vivo.
Whereas BALB/c mice are resistant to bleomycin-induced pulmonary
ﬁbrosis [84], transient overexpression of CTGF in the lungs of these
“ﬁbrosis-resistant” mice by adenoviral gene transfer of CTGF enabled
bleomycin to induce pulmonary myoﬁbroblast accumulation and ﬁ-
brosis similar in extent to that produced in “ﬁbrosis-prone” C57Bl/6
mice [85]. The pro-ﬁbrotic effects of CTGF that is speciﬁcally
expressed by pulmonary epithelial cells were demonstrated in a
transgenic mouse model with doxycycline-inducible overexpression
of CTGF in respiratory epithelial cells directed by the clara cell secreto-
ry protein promoter. Overexpression of CTGF from postnatal days 1–14
resulted in increased αSMA expression, collagen deposition and dra-
matic thickening in the peribronchial/peribronchiolar and perivascular
regions of the lungs [86]. Cooperation between the pro-ﬁbrotic effects
of TGF-β and CTGF has also been noted in vivo. Intraperitoneal
co-administration of CTGF and TGF-β2 induced multiorgan ﬁbrosis in
the lungs, liver and kidneys, whereas administration of either cytokine
alone failed to elicit a ﬁbrotic response [87]. Conversely, anti-CTGF an-
tibodies have been shown to mitigate the increases in αSMA and type I
collagen protein expression, as well as total collagen content, induced
in lung in the bleomycin model of pulmonary ﬁbrosis [88,89].
3.3. Sonic hedgehog (Shh)
Some of the pathways that regulate embryological development
but are subsequently quiescent appear to re-emerge during repair
responses to tissue injury [90]. Consistent with re-activation of devel-
opmental pathways in response to injury, microarray analyses of IPF
gene expression revealed enriched expression of genes associated
with lung development, including Patched-1, a receptor in the hedge-
hog pathway [91]. The hedgehog (Hh) family in mammals consists of
sonic hedgehog (Shh), desert hedgehog (Dhh), and indian hedgehog
(Ihh), which play critical roles in embryonic development, tissue
patterning, and organogenesis [92,93]. Of these three mammalian
Hh homologues, Shh has been shown to be responsible for tissue
patterning in the lung, by regulating branching morphogenesis
[94–96]. During lung development, Shh is produced in the distal
epithelium and stimulates mesenchymal cell proliferation. Shh
overexpression in mice pre-natally results in lethally excessive accu-
mulation of lung interstitial mesenchyme [96], emphasizing that the
Shh pathway mediates important epithelial cell-to-mesenchymal
cell interactions during embryological lung development.
3.3.1. Epithelial cell synthesis of Shh
In both lung development and pulmonary ﬁbrosis, epithelial cells
appear to be the major source of Shh. During embryological develop-
ment, low levels of ShhmRNA are present throughout the epithelium,
and high levels are present at the tips of the terminal buds that ulti-
mately form alveoli [23,97]. Several studies of lung tissues obtained
from IPF patients have demonstrated high Shh expression in reactive
AECs, as well as in the epithelial cells that line honeycomb cysts, com-
pared with little or no Shh expression in normal adult lung tissues
[98–100]. In contrast, another recent study found that most of the
components of the Shh system were expressed in normal adult alveo-
lar epithelium, but that this pathway was activated speciﬁcally in IPF
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of the Shh pathway in pulmonary ﬁbrosis, both TGF-β and hydrogen
peroxise (H2O2) have been reported to modulate Shh production
by AECs [102,103]. Although short-term incubation with TGF-β has
been noted to suppress the secretion of Shh protein without signiﬁ-
cantly changing Shh mRNA expression [102], chronic TGF-β exposure
dramatically increases expression of Shh both at the mRNA and
protein levels [103]. In contrast, H2O2 enhances the release of Shh
protein from epithelial cells without changing Shh mRNA expression,
suggesting that H2O2 induces release of pre-formed Shh from intra-
cellular stores [102].
3.3.2. Pro-ﬁbrotic effects of Shh on ﬁbroblasts
Shh signaling is transduced by 2 transmembrane proteins,
patched-1 (PTCH-1) and smoothened (SMO). PTCH-1 is an Shh-
binding receptor, which in the absence of Shh constitutively blocks
SMO activity. Shh binding to PTCH-1 activates SMO, and activated
SMO directs the biochemical processing and subsequent nuclear
translocation of the transcription factors glioma-associated oncogene
homolog (GLI)1, GLI2, and GLI3 Target genes regulated by these tran-
scription factors include PTCH-1 itself, as well as regulators of the
cell cycle, enabling the Shh pathway to regulate cell proliferation
[104–106]. One recent immunohistochemical analysis of Shh path-
way components in IPF reported ﬁbroblast expression of PTCH-1,
SMO, and GLI1 in the lungs of IPF patients, whereas no staining was
detected in normal lungs [100]. PTCH-1 mRNA was also upregulated
in primary lung ﬁbroblasts grown from IPF versus normal lung tissue,
and in ﬁbroblasts assessed by laser capture microdissection in IPF
lung tissues versus lung tissues from patients with cryptogenic orga-
nizing pneumonia [100]. In vitro, recombinant SHH has recently been
shown to increase ﬁbroblast proliferation and migration, to increase ﬁ-
broblast expression of collagen and ﬁbronectin but not αSMA, and to
protect ﬁbroblasts from apoptosis [100]. Additionally, TGF-β1's ability
to drive and maintain myoﬁbroblast differentiation was recently
demonstrated to require SMO/GLI pathway activity [101].
3.4. Prostaglandin E2 (PGE2)
The paucity of ﬁbroblasts in normal alveolar septae compared
with the greater abundance of ﬁbroblasts in the connective tissue sur-
rounding pulmonary bronchi, arteries, and veins led some investiga-
tors to hypothesize that under homeostatic conditions, alveolar
epithelial cells suppress ﬁbroblast accumulation. Media conditioned
by AEC-ﬁbroblast co-culture was in fact demonstrated to inhibit ﬁ-
broblast proliferation, and this inhibition in subsequent studies was
determined to be attributable to PGE2 synthesized by AECs [24,107].
In contrast to the pro-ﬁbrotic epithelial cell-to-ﬁbroblast interactions
mediated by TGF-β, CTGF and Shh, PGE2 therefore carries anti-ﬁbrotic
signals from epithelial cells to ﬁbroblasts.
3.4.1. Epithelial cell synthesis of PGE2
AECs have a large capacity for synthesizing PGE2, the most abun-
dant arachidonic acid metabolite that these cells produce. Following
the liberation of arachidonic acid from membrane phospholipids,
the synthesis of prostanoids, including prostaglandins, thromboxane
and prostacyclin, is initiated by two cyclooxygenase (COX) enzymes,
COX-1 and COX-2. COX-1 is constitutively expressed in most cells
and tissues, whereas COX-2 is expressed when induced by inﬂamma-
tory or mitogenic stimuli [108]. The pulmonary epithelium represents
an exception to this usual pattern, in that AECs constitutively express
both COX isoforms [109]. Experiments using COX-2-deﬁcient AECs
demonstrated that the PGE2 synthetic capacity of these cells is pre-
dominantly COX-2-dependent [24].
PGE2 synthesis is reduced in IPF, limiting the anti-ﬁbrotic epithelial
cell-to-ﬁbroblast interactions that are mediated by PGE2. PGE2 levels
in the epithelial lining ﬂuid of individuals with IPF were found to be50% lower than those in normal subjects [110]. AEC production of
PGE2may be suppressed by increased levels of plasminogen activation
inhibitor-1 (PAI-1) and CC chemokine ligand 2 (CCL2) in IPF lungs.
Plasmin has recently been shown to upregulate AEC PGE2 produc-
tion [111]. Plasmin upregulates AEC COX-2 expression, potentially
through its ability to proteolytically activate and release hepatocyte
growth factor (HGF) from these cells and/or the extracellular matrix.
In bronchial epithelial cells, HGF has been shown to increase COX-2
gene expression through an Akt-, MAPK-, and β-catenin-dependent
pathway [112]. PAI-1, which is markedly upregulated in ﬁbrotic
lungs [113], prevents the generation of plasmin by inhibiting
urokinase-type plasminogen activator (uPA). By reducing the genera-
tion of plasmin, increased levels of PAI-1 could therefore reduce AEC
PGE2 synthesis in IPF. In support of this hypothesis, PAI-1-deﬁcient
mice demonstrate increased lung production of PGE2, and are
protected from bleomycin-induced pulmonary ﬁbrosis [111]. This
protection was abrogated by a selective inhibitor of the HGF receptor
c-Met, which reduced lung COX-2 and PGE2 levels. In contrast to its
upregulation by plasmin, AEC PGE2 synthesis is downregulated by
CCL2. CCL2 is present in increased amounts in the bronchoalveolar
lavage ﬂuid of IPF patients [114], and may be induced in the AECs
themselves by thrombin activation of the major thrombin receptor,
proteinase-activated receptor-1 (PAR1) [115]. CCL2 and PAR1 are
co-expressed and co-upregulated on the activated epithelium in ﬁ-
brotic areas in IPF, and thrombin potently induces CCL2 expression
in lung epithelial cells in vitro in a PAR1-dependent manner.
3.4.2. Anti-ﬁbrotic effects of PGE2 on ﬁbroblasts
PGE2 has been demonstrated to have multiple activities on ﬁbro-
blasts that could suppress ﬁbrosis, including inhibition of ﬁbroblast
migration [116], proliferation [117,118], collagen synthesis [119],
and myoﬁbroblast differentiation [120]. Of the 4 E prostanoid (EP)
receptors, designated EP1, EP2, EP3, and EP4 [120], these inhibitory
effects of PGE2 on ﬁbroblasts are mediated by EP2 [120–122]. Lung
ﬁbroblast EP2 expression, however, is downregulated in pulmonary
ﬁbrosis. Diminished EP2 levels in ﬁbroblasts isolated from mouse
lungs following bleomycin challenge reduced the ability of PGE2 to in-
hibit their proliferation and collagen secretion [121]. Fibroblasts iso-
lated from patients with IPF also exhibit decreased EP2 expression,
and are similarly refractory to the anti-ﬁbrotic effects of PGE2 [123].
The diminished EP2 expression levels in ﬁbroblasts from ﬁbrotic
lungs are maintained by hypermethylation of the PGE receptor 2
gene (PTGER2) promoter [124]. Treatment of these ﬁbroblasts with
DNA methylation inhibitors or DNA methyltransferase-speciﬁc siRNA
decreased PTGER2 methylation, increased EP2 mRNA and protein ex-
pression, and restored PGE2 responsiveness [124]. The anti-ﬁbrotic
epithelial cell-to-ﬁbroblast interactionsmediated by PGE2 therefore ap-
pear to be limited in IPF by decreased ﬁbroblast EP2 expression as well
as by decreased AEC PGE2 synthesis. Whereas epithelial-to-ﬁbroblast
interactions mediated by TGF-β, CTGF and Shh are attractive targets
for new IPF therapies to inhibit, restoring PGE2-mediated interactions,
by increasing AEC PGE2 production and ﬁbroblast EP2 expression, rep-
resents an attractive therapeutic strategy for pulmonary ﬁbrosis.
4. Fibroblast-to-epithelial cell interactions: how activated
ﬁbroblasts injure epithelial cells
As noted above, recurrent and/or non-resolving injury to the lung
epithelium now appears to be the “prime mover” of pulmonary ﬁbro-
sis. Increased numbers of apoptotic cells have been observed in the
alveolar and bronchial epithelia of IPF patients [4,5], and the speciﬁc
induction of epithelial injury and/or apoptosis has been shown to
be sufﬁcient to cause pulmonary ﬁbrosis in several mouse models
[9–12]. Although the initiating causes of epithelial injury in IPF remain
enigmatic, activated ﬁbroblasts appear to be able to amplify the epi-
thelial apoptosis that results. As also noted above, the co-localization
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IPF lungs [6] makes the paracrine interaction of these two cell types
plausible in the development of ﬁbrosis in vivo. The ability of activated
ﬁbroblasts to affect epithelial cells in a paracrine fashion has been
demonstrated in vitro. In these experiments, media conditioned by
ﬁbroblasts isolated from the lungs of IPF patients markedly induced
apoptosis of AECs in culture, whereas media conditioned by ﬁbro-
blasts from control subjects did not [125]. Several mediators have
been found to be responsible for this ability of activated ﬁbroblasts
to induce epithelial cell apoptosis, including angiotensin II and hydro-
gen peroxide (H2O2) (Fig. 1).
4.1. Angiotensin II
The renin–angiotensin system consists of renin, angiotensinogen
(AGT), angiotensin I (ANG I), angiotensin converting enzyme (ACE)
and angiotensin II (ANG II). The octapeptide ANG II is the primary ef-
fector molecule of this pathway, and is formed by enzymatic cleavage
of AGT to ANG I by the aspartyl protease renin, followed by the con-
version of ANG I to ANG II by ACE. Although best known for its role
in blood pressure regulation due to its ability to mediate vasocon-
striction, ANG II has been implicated in the pathogenesis of ﬁbrotic
diseases affecting multiple organs, including the lung [126].
4.1.1. Fibroblast synthesis of ANG II
ANG II was determined to be the soluble factor responsible for
inducing AEC apoptosis in media conditioned by IPF lung ﬁbroblasts
[127]. Lung tissue from IPF patients and bleomycin-challenged mice
demonstrate upregulation of AGT and ANG peptides speciﬁcally in
myoﬁbroblasts [128,129]. In vitro, human lung ﬁbroblasts have been
demonstrated to upregulate AGT expression in response to TGF-β,
through a mechanism involving activation of AGT transcription by
hypoxia-inducible factor-1α and Jun D [130]. Myoﬁbroblasts, espe-
cially under hypoxic conditions, are consequently thought to be an
important source of ANG II production in the ﬁbrosing lung.
4.1.2. Pro-ﬁbrotic effects of angiotensin II on alveolar epithelial cells
The biological effects of ANG II are mediated through its two spe-
ciﬁc G protein-coupled seven transmembrane domain receptors, ANG
II type 1 receptor (AT1R) and ANG II type 2 receptor (AT2R) [126].
Although AECs express both AT1R and AT2R, experiments with AT1R-
and AT2R-selective antagonists indicate that AT1R mediates ANG
II-induced AEC apoptosis [131,132]. An AT1R-selective antagonist was
able to preventmouse AEC apoptosis and lung ﬁbrosis in the bleomycin
model, as was an antisense oligonucleotide targeting AGT mRNA
and an ACE inhibitor [128,133,134]. AT1R-deﬁcient mice similarly
demonstrated reduced AEC apoptosis and collagen accumulation in
the bleomycin model [134]. Further implicating the renin–angiotensin
system in IPF, a single-nucleotide polymorphism (SNP) in the promoter
region of the AGT gene that increases AGT transcription has been asso-
ciated with more rapid disease progression [135].
4.2. Reactive oxygen species (ROS)
Experiments co-culturing small airway epithelial cells with TGF-β-
stimulated ﬁbroblasts isolated from IPF patients identiﬁed hydrogen
peroxide (H2O2) as another diffusible paracrine signal produced by ac-
tivatedmyoﬁbroblasts that is able to induce epithelial cell death [136].
Production of ROS, such as H2O2, superoxide anions (∙O2−) and hydrox-
yl radicals (∙OH), in excess of the capacity of cells and tissues to detox-
ify or scavenge them is referred to as “oxidative stress”, and has been
implicated in ﬁbrotic diseases of multiple organs, including the
lung [137]. Multiple lines of evidence indicate the presence of
oxidative stress in IPF lungs. H2O2 concentrations are signiﬁcantly
higher in the exhaled breath condensates of IPF patients than control
subjects, and correlate with disease severity [138]. Proteins in thebronchoalveolar lavage ﬂuid of IPF patients demonstrate elevated
levels of oxidative changes, such as oxidation of methionine residues
to methionine sulfoxide, and introduction of carbonyl groups into
other amino acid side-chains [139,140]. Additionally, epithelial cells in
the lungs of IPF patients demonstrate the presence of ROS-induced
DNA modiﬁcations [141].
4.2.1. Fibroblast synthesis of ROS
ROS are formed by the univalent reduction of oxygen, generally
mediated by several ROS-producing enzymes, such as mitochondrial
respiratory oxidases, xanthine oxidase, myeloperoxidase and NADPH
oxidases [137,142]. NADPH oxidases comprise a seven member fami-
ly, including NOX1, 2, 3, 4 and 5, Duox1 and 2. Both NOX1 and NOX2
generate superoxide anions, whereas NOX4 produces H2O2 [143].
Recent evidence has implicated NOX4 expressed by ﬁbroblasts in the
development of lung ﬁbrosis. TGF-β induces expression of this NOX
isoform in IPF lung ﬁbroblasts in vitro. Further, the expression αSMA
and extracellular matrix proteins induced in lung ﬁbroblasts by
TGF-β, as well as the proliferation of these cells induced by serum, re-
quire NOX4-dependent generation of H2O2 [144]. In IPF lung sections,
H2O2 localizes speciﬁcally to αSMA-expressing myoﬁbroblasts [136],
and NOX4 similarly localizes to myoﬁbroblastic foci [144]. A critically
important role for ﬁbroblast NOX4, and the H2O2 it produces, in the
pathogenesis of pulmonary ﬁbrosis was demonstrated in experiments
inwhich siRNA-mediated knockdown of NOX4 expression suppressed
ﬁbrosis in vivo in both bleomycin- and FITC-induced mouse models of
pulmonary ﬁbrosis [144].
4.2.2. Pro-ﬁbrotic effects of ROS on alveolar epithelial cells
In cultures of conﬂuent primary distal lung epithelial cells, exoge-
nous H2O2 inhibits monolayer closure after scratch wounding by
inducing epithelial cell apoptosis [145]. As noted above, co-culture
experiments demonstrated that endogenous generation of H2O2 by
TGF-β-stimulated IPF lung ﬁbroblasts induces apoptosis of small air-
way epithelial cells in a paracrine manner [136]. In the bleomycin
mouse model of pulmonary ﬁbrosis, alveolar epithelial apoptosis
induced in vivo by bleomycin injury was demonstrated to be NOX4-
dependent. The dramatic increase in apoptotic alveolar epithelial cells
observed in wild type mice at early time points post-bleomycin chal-
lenge was abrogated in NOX4-deﬁcient mice, and the development of
ﬁbrosis in these mice was markedly reduced at later time points
[146]. A pathogenic role for ROS in pulmonary ﬁbrosis in vivo studies
has been further underscored by the amelioration of bleomycin-
induced ﬁbrosis in mice administered the antioxidant superoxide
dismutase, and the exacerbation of bleomycin-induced pulmonary
ﬁbrosis in mice genetically deﬁcient for this enzyme [147,148].
5. Bidirectional epithelial cell-ﬁbroblast interactions in
pulmonary ﬁbrosis
Many importantmediators of pulmonary ﬁbrosis may be produced
by both epithelial cells and ﬁbroblasts, and may exert important ef-
fects on both cell types as well. Several of the signaling molecules
discussed above carry signals both from epithelial cells to ﬁbroblasts
and from ﬁbroblasts to epithelial cells, thus mediating bidirectional
epithelial cell-ﬁbroblast interactions in pulmonary ﬁbrosis.
5.1. TGF-β
As described above, TGF-β is activated during the development of
pulmonary ﬁbrosis by epithelial cell integrins, and induces multiple
pro-ﬁbrotic activities in ﬁbroblasts, including their recruitment,
proliferation, myoﬁbroblast differentiation and extracellular matrix
production [33]. In addition to mediating these pro-ﬁbrotic effects
on ﬁbroblasts, TGF-β delivers pro-ﬁbrotic signals to the alveolar epi-
thelium. In contrast to its induction of resistance to apoptosis in
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in vitro [149,150]. A pathogenic role for TGF-β-induced epithelial cell
apoptosis is suggested by observations of mice with lung-speciﬁc
overexpression of active TGF-β. In these mice, a transient wave of
epithelial apoptosis precedes the development of lung ﬁbrosis, and
blocking the TGF-β-induced epithelial apoptosis by administration of
a general or a 3/7-selective caspase inhibitor markedly ameliorated
the subsequent ﬁbrosis. A pathogenic role for TGF-β-induced epithelial
cell apoptosis is further suggested by the protection from bleomycin-
induced ﬁbrosis observed in mice with epithelial cell-speciﬁc deletion
of TGF-β type II receptor [151]. Lung ﬁbroblasts produce TGF-β latent
complexes, and have been shown to be able to activate these complexes
themselves by theανβ5 integrins that they express [152]. TGF-β there-
fore could very plausibly mediate pro-ﬁbrotic ﬁbroblast-to-epithelial
cells interactions, in which TGF-β produced and activated by lung ﬁbro-
blasts mediates epithelial cell apoptosis. TGF-β thus could be an impor-
tant mediator of bidirectional interactions between epithelial cells and
ﬁbroblasts in pulmonary ﬁbrosis.
5.2. ANG II
As noted above, ANG II produced by myoﬁbroblasts induces apo-
ptosis in alveolar epithelial cells in a paracrine fashion. In addition
to mediating this pro-ﬁbrotic effect of ﬁbroblasts on epithelial cells,
ANG II may also carry pro-ﬁbrotic signals from epithelial cells to ﬁbro-
blasts. Apoptotic AECs have been shown to produce AGT and convert
it to ANG II both in vitro and in the lung [129,153]. Lung ﬁbroblasts
express AT1R and AT2R, and ANG II-AT1R signaling induces multiple
pro-ﬁbrotic activities in cells, including their proliferation, migration,
and extracellular matrix synthesis [129]. ANG II therefore could
also mediate pro-ﬁbrotic effects of epithelial cells on ﬁbroblasts, in
which case it would also be an important mediator of bidirectional
interactions between these two cell types in pulmonary ﬁbrosis.
6. Other mediators of epithelial cell-ﬁbroblast interactions in
pulmonary ﬁbrosis
The signaling molecules discussed in this review are meant
to serve as important examples, rather than as a complete list, of me-
diators that direct epithelial cell-ﬁbroblast interactions in lung ﬁbro-
sis. Multiple other pathways that may contribute to the pro-ﬁbrotic
interactions of these two cell types have been described. Additional
examples of important such signaling molecules include members
of the WNT pathway and of the found in inﬂammatory zone (FIZZ)/
resistin-like molecule (RELM) family. The WNT pathway was recently
demonstrated to deliver pro-ﬁbrotic signals from epithelial cells to
ﬁbroblasts in the development of lung ﬁbrosis [154]. Expression of ca-
nonical (β-catenin-dependent) WNT signaling components and the
WNT pathway target molecule, WNT-1-inducible signaling protein-1
(WISP1, another member of the CCN family of matricellular proteins),
are strongly upregulated in type II AECs in both mice challenged with
bleomycin and humans with IPF [154]. Alveolar epithelial cell WISP1
can exert pro-ﬁbrotic effects on lung ﬁbroblasts: WISP1 stimulates ﬁ-
broblast extracellular matrix synthesis and myoﬁbroblast differentia-
tion in vitro, and its neutralization suppresses bleomycin-induced
lungﬁbrosis inmice in vivo [154]. FIZZ/RELM familymembers, including
FIZZ1/RELM-α and FIZZ2/RELM-β, similarly have been shown to be
expressed by pulmonary epithelial cells during the development of ﬁ-
brosis, and to exert pro-ﬁbrotic effects on ﬁbroblasts. FIZZ1 is strongly
induced in mouse AECs following bleomycin challenge [155], and
induces ﬁbroblast extracellular matrix production, myoﬁbroblast
differentiation, and resistance to apoptosis [155–157]. FIZZ2 can also
be induced in lung epithelial cells, is highly expressed in the lungs of
bleomycin-challenged mice and IPF patients, and stimulates ﬁbroblast
type I collagen synthesis and myoﬁbroblast differentiation; genetic
deletion of FIZZ2 signiﬁcantly attenuates pulmonary ﬁbrosis in thebleomycinmousemodel [158].We expect that the number of pathways
found to contribute to the pro-ﬁbrotic interactions between epithelial
cells and ﬁbroblasts will continue to grow as investigators continue to
unravel the complex pathogenesis of pulmonary ﬁbrosis.
7. Epithelial cell-ﬁbroblast interaction as a common theme in the
development of organ ﬁbrosis
Epithelial cell-ﬁbroblast (and mesothelial cell-ﬁbroblast) interac-
tions may importantly contribute to the pathogenesis of ﬁbrotic
diseases in multiple organs. These interactions may be particularly
relevant in organs in which ﬁbroblasts and epithelial cells (or meso-
thelial cells) normally reside in close proximity, such as the lung, kid-
ney, liver and peritoneum.
Progressive and potentially lethal renal ﬁbrosis occurs in diverse
kidney diseases. Renal ﬁbrosis most often involves the accumulation
of ﬁbroblasts and extracellular matrix in the tubular interstitium,
and atrophy of the tubular epithelium. The degree of renal ﬁbrosis
correlates well with the prognosis of the renal diseases in which it is
found, independent of their etiologies [159]. Accumulating evidence in-
dicates that injured renal tubular epithelial cells activate and/or
upregulate mediators such as TGF-β and CTGF that deliver pro-ﬁbrotic
signals to neighboring ﬁbroblasts [160]. Apoptosis of renal tubular epi-
thelial cells contributes to the progression of renal ﬁbrosis [161], and
both ANG II and ROS have been shown to induce apoptosis in these ep-
ithelial cells [162–164], as they do in alveolar epithelial cells in pulmo-
nary ﬁbrosis.
Epithelial cell-ﬁbroblast interactions analogous to those occurring
in IPF also appear to be important in the pathogenesis of hepatic and
biliary ﬁbrosis [165–167]. Hepatocyte injury and death leading to he-
patic stellate cell activation in viral or toxin-induced hepatic ﬁbrosis
is analogous in many ways to AEC injury activating myoﬁbroblasts
in pulmonary ﬁbrosis. In the case of biliary ﬁbrosis, it is injury to
cholangiocytes that leads to the activation and/or upregulation of
mediators such TGF-β and CTGF that promote the activation and
recruitment of hepatic stellate cells and portal ﬁbroblasts [165].
Moreover, ανβ6 integrin expression is upregulated by cholangiocytes
in mouse models of biliary ﬁbrosis, and contributes to the ability of
these cells to activate latent TGF-β [168]. Biliary ﬁbrosis produced in
mice in vivo by bile duct ligation was signiﬁcantly reduced in β6
integrin-deﬁcient mice, and by administration of a blocking antibody
to ανβ6 [169].
Peritoneal ﬁbrosis is an important problem following acute perito-
neal injury, as in the development of adhesions post-abdominal sur-
gery, and following chronic peritoneal injury, as in the development
of peritoneal ﬁbrosis post-chronic peritoneal dialysis [170,171]. In
the normal peritoneum, ﬁbroblasts reside in a thin interstitial layer
adjacent to the mesothelial cell monolayer. In the case of peritoneal
dialysis-induced ﬁbrosis, dialysis solutions that are hyperosmotic,
hyperglycemic and/or acidic chronically injure the mesothelial cell
layer, causing these cells to elaborate pro-ﬁbrotic mediators including
CTGF that drives peritoneal ﬁbroblast proliferation and matrix depo-
sition, resulting in progressive ﬁbrotic expansion of the peritoneal
interstitium [170,172,173].
8. Concluding remarks
IPF remains a devastating disease that as yet is without effective
pharmacological therapy, despite intensive scientiﬁc and clinical in-
vestigation. Although the stimuli that initiate epithelial injury in IPF
have yet to be identiﬁed, substantial evidence supports the hypothe-
sis that progression of IPF is driven by a series of pro-ﬁbrotic epithe-
lial cell-ﬁbroblast interactions. In a “pas de deux”, or “folie à deux”, of
epithelial cells and ﬁbroblasts, interactions between these two cell
types create a vicious cycle in which repetitive cycles of AEC injury
provoke the activation of ﬁbroblasts, and these activated ﬁbroblasts
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represent attractive therapeutic targets for treatment of pulmonary
ﬁbrosis, as well as for ﬁbrotic diseases of other organs such as the kid-
ney and liver where epithelial cell-ﬁbroblast interactions appear to be
central to the pathogenesis of ﬁbrosis. Several of the mediators of
these interactions discussed in this review are already being targeted
by drugs in various stages of evaluation for IPF and/or other ﬁbrotic
diseases: TGF-β signaling is the target of the anti-ανβ6 integrin anti-
body STX-100 (Stromedix/Biogen Idec), the anti-TGF-β antibodies
GC-1008 (Genzyme) and LY2382770 (Lilly), and one of the targets of
pirfenidone (InterMune); CTGF is the target of the anti-CTGF antibody
FG-3019 (FibroGen); ROS are the target of N-acetylcysteine given to
augment lung anti-oxidant defense; and Ang II signaling is the target
of the angiotensin II receptor antagonist losartan [174,175]. An even
greater understanding of epithelial cell-ﬁbroblast interactions in ﬁbro-
sis will facilitate the development of additional strategies to therapeuti-
cally target the signaling molecules that mediate these interactions.
Given the complexities of these interactions, with multiple mediators
involved and at least some carrying bi-directional signals to and from
each cell type, a better mapping of the steps that epithelial cells and
ﬁbroblasts take in their “ﬁbrosis of two” will increase the likelihood of
success of the mounting efforts to develop effective new anti-ﬁbrotic
therapies.
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